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Abstract
Although visual  problems  are  reported  by  patients  with  Alzheimer’s  disease  and
dementia, studies into this particular aspect of neuropathology are scarce. The growing
awareness of complex pathological processes in the ageing retina and brain, however,
enables us to consider this from a new perspective. Here we discuss the latest findings
on the wide-ranging visual defects experienced by those suffering from Alzheimer’s
disease and dementia. We propose that events leading to chronic degeneration of the
retina and the brain in fact share many striking similarities. In particular, we discuss
the role of the Alzheimer’s-related amyloid beta (Aβ) group of peptides that has been
shown to accumulate in senescent retinas,  correlated with increased risk of retinal
degeneration. The high photo-oxidative retinal environment creates ideal conditions
for Aβ aggregation, evidenced by high Aβ loads reported in aged and donor eyes from
patients with age-related macular degeneration. Consequently, longitudinal and non-
invasive  retinal  assessments  may  provide  invaluable  information  on  incipient
pathology and disease progression in the retina as well as the senescent brain. Such
insights may not only lead to identifying new pathogenic mechanisms in the retina with
implications for understanding Alzheimer’s disease but reveal the underlying causes
of visual abnormalities reported in patients with dementia.
Keywords: amyloid beta, retina, degeneration, Alzheimer’s, age-related macular de‐
generation
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1. Introduction
Dementia poses a significant risk to those over the age of 65, affecting up to 46.8 million individuals
globally, a number that is expected to increase to approximately 131 million by 2050 [https://
www.alz.co.uk/research/WorldAlzheimerReport2015.pdf]. Currently, no reliable treatments
exist, although it has been estimated that slowing disease progression by just 5 years would
reduce  the  number  of  dementia-related  deaths  by  almost  half  [https://www.alzheim‐
ers.org.uk]. Alzheimer’s disease (AD) is an age-related neurodegenerative disorder of the brain,
and the most common cause of dementia amongst the elderly [1]. AD is typified by progres‐
sive memory loss and significant cognitive decline amongst other complications that ultimate‐
ly leads to death [2].
A major pathological feature of AD is misfolding and aggregation of the naturally occurring
amyloid beta (Aβ) family of proteins. A variety of different Aβ peptides are generated by
successive proteolytic cleavage of the amyloid precursor protein (APP). These accumulate as
large insoluble aggregates in AD brains and are referred to as ‘senile plaques’. The amyloid
cascade hypothesis proposes that Aβ plays a central role in AD [2]. However, AD and dementia
are complex diseases, and the role of Aβ and other disease factors are still incompletely
understood. Studies are also hampered by the brain’s relative inaccessibility, and clinical
diagnosis typically occurs many years after disease onset [3]. Consequently, there is consid‐
erable impetus towards developing non-invasive, reliable and cost-effective diagnostic
methods so those at risk may be identified at relatively early stages to maximise the chances
of clinical intervention. Most studies into AD and dementia are primarily focused on memory
loss and cognitive decline [4, 5]. However, many AD patients are also reported to suffer from
a variety of visual complications, which by contrast has received comparatively little attention.
The recent discovery that Aβ deposits in the ageing human retina correlate with complex
retinopathies such as age-related macular degeneration (AMD) has given support to the
hypothesis that shared pathologies may exist between the brain and senescent retina.
In this chapter, we provide a comprehensive review of the latest findings reporting visual
abnormalities in patients with AD and dementia. The methodology for this review is based on
searches conducted in the NCBI PubMed (http://www.ncbi.nlm.nih.gov/pubmed) database
using keywords ‘dementia and retina’ (396 articles) and ‘AD and retina’ (457 articles) in June
2016. These numbers contrast starkly with larger numbers of studies in areas related to memory
loss and cognitive decline. For example, use of keywords ‘dementia and memory loss’ (12,383
articles) or ‘AD and cognitive impairment’ (19,883 articles) yield many more citations;
highlighting the as yet limited interest in systematically reporting visual abnormalities in AD
and dementia patients. Additionally, we used keywords such as ‘retina and Aβ’ (111 articles)
and ‘retinal pigment epithelium (RPE) and amyloid’ (59 citations) to include specific articles
related to ophthalmology and dementia, and to describe studies in ex vivo and animal models
that provide insights into Aβ-mediated pathogenesis. Centring on these articles, specific
information in hyperlinks, as well as insights from our own work, we discuss the role of Aβ
in driving retinal degeneration and neurodegeneration, and propose that the eye may provide
a powerful model to study Aβ pathology. We suggest that the retina may act as an anatomical
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window into the Alzheimer’s brain through which early stages of neurodegeneration could
non-invasively be identified.
2. The ageing brain and retina: intimate connections
The neuroretina and the central nervous system (CNS) share common origins as both derive
from the developing neural ectoderm and maintain a direct and permanent connection via the
optic nerve [6]. The neuroretina may therefore be considered an extension of the brain that
resides within a discrete compartment—the eye. In addition to this anatomical link, both the
retina and tissues of the CNS exhibit similar structural and functional arrangements. These
include specialised structural adaptations such as surface infolds, postmitotic neuronal and
epithelial cells, immunologically privileged compartmentalisation via a blood-brain/retinal
barrier, as well as more importantly, similar patterns of damage with increasing age [7]. It is
therefore possible that common disease mechanisms may also be involved in diseases of the
ageing eye and brain.
Gathering of visual information first occurs when light enters the eye’s anterior pole and is
projected to the neuroretina. Here, incident light is converted by specialised photoreceptors
in the neuroretina into electrical impulses which are subsequently relayed to second- and third-
order neurons [8] (Figure 1). Axons of retinal ganglion cells (RGCs) then convey these signals
to the brain. The synaptic arrangement in the neuroretina comprises of three sequential
neuronal layers: photoreceptors, bipolar, and RGCs (referred to as the three neuron links) [9].
Neuronal cell bodies and processes exist in alternate layers giving rise to the laminated
structure of the retina where cell bodies typically exist within the inner and outer nuclear
layers, whereas processes and synapses of retinal neurons reside within the inner and outer
plexiform layers [10]. In addition to these cell types, specialised neurons referred to as amacrine
and horizontal cells facilitate the parallel processing of information [9]. Furthermore, a highly
specialised monolayer of epithelial cells which originates from the neuroectoderm referred to
as the RPE forms the margins of the outer retina and the interface with the outer vasculature
(Figure 1) [11]. Here, within this strategic position, the RPE performs many critical metabolic
and supportive functions for the overlying neuroretina. These include the absorption of stray
light, phagocytosis of shed photoreceptor outer segments (POS) as part of the daily visual
cycle, maintenance of the blood-retinal barrier (BRB), ion homeostasis as well as playing a role
in retinal adhesion [11, 12]. The normal function of the RPE monolayer is therefore critical to
maintain healthy vision in old age.
The arrangement of the mammalian retina is such that light must first traverse the entire length
of the retina before reaching the photoreceptors. Two distinct types of photoreceptors exist
which may be categorised according to histological morphology and which are each special‐
ised for a specific function. Rod photoreceptors constitute 95% of all photoreceptors, express
the photopigment rhodopsin and are responsible for scotopic (low light) visual processes [13].
Cone photoreceptors on the other hand encompass a highly invaginated membrane to provide
an optimal surface area for phototransduction and are responsible for photopic (normal/high
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light) visual processes, the perception of colour and visual acuity. Colour vision is achieved
through expression of the photopigment opsin, which, depending on the structure of the
molecule, confers sensitivity to varying wavelengths of light [9]. Cone photoreceptors typically
concentrate within the fovea—an area corresponding to 1.5 mm in diameter at the centre of
the human retina where light from the central visual field is focused and which is responsible
for high visual acuity and detailed image perception [14]. Within this area, the retina is devoid
of the inner retinal layers and retinal vasculature, which ensures minimal interference to
focused light when creating a clear foveal image [9]. The region peripheral to the fovea is
termed the macula which has a high proportion of cones that extends to a radius of 5.5 mm in
diameter [14].
Figure 1. Synaptic arrangement of the neuroretina and associated layers. Diagram illustrating the inverted arrange‐
ment of the human neuroretina with light-sensitive photoreceptors forming intimate associations with the underlying
retinal pigment epithelium (RPE).
The axons of the RGCs converge at the centre of the retina where they exit the eye through the
optic disc and maintain a permanent connection with the brain via the optic nerves (Figure 2)
[15]. The optic nerve (also referred to as the second cranial nerve) enters the cranial cavity via
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the optic canal where it runs parallel to the middle cranial fossa in close proximity to the
pituitary gland. Anterior to the stalk of the pituitary gland, an anatomical crossroad exists
known as the optic chiasm, where optic nerves unite and axons from RGCs that reside within
the nasal side of both left and right retinas connect with the opposing hemisphere of the brain
(Figure 2). Conversely, temporal RGC axons project to its corresponding cerebral hemisphere.
Soon after exiting the optic chiasm, the RGC axons converge to form the optic tract which
predominantly synapses with the lateral geniculate nucleus (LGN), a relay centre for the visual
pathway that resides within the thalamus. The internal structure of the LGN comprises several
layers which function as maps of visual space and which segregate information according to
axonal origin. As the LGN receives information from the right and left visual fields, visual
input from the opposing hemisphere is kept separate from that of the corresponding eye. This
information is then passed to the visual cortex within the posterior brain for processing via
optic radiations formed by the axons of the LGN neurons (Figure 2). Here, segregation of visual
information is maintained according to the location in the retina from which information was
perceived. For example, information derived from the fovea occupies a significant area of the
posterior visual cortex, whereas progressively more anterior regions of the visual cortex
represent visual perceptions from the periphery of the retina. Several other regions of the brain
are innervated from the visual cortex including the occipital, parietal and temporal lobes. These
areas are linked with visuoperceptual and visuospatial aspects of vision, as well as visual
acuity and the recognition of familiar objects [16, 17].
Figure 2. Synaptic terminals of the optic nerve and visual pathway in the brain.
RGC axons within the optic tracts also connect with several diencephalic and midbrain
structures. These include the superior colliculi (SC), also termed the optic tectum which is
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situated on the roof of the midbrain and is involved in controlling eye movement; the supra‐
chiasmatic nucleus (SCN) which is a small, wing-shaped structure within the hypothalamus
located directly above the optic chiasm that is involved in circadian rhythm; and nuclei within
the midbrain that are implicated in controlling pupil diameter (Figure 2). Of note, several of
these aforementioned visual centres have been associated with AD pathology. For instance,
the SC has been shown to progressively accumulate both Alzheimer-associated senile plaques
as well as neurofibrillary tangles (NFT). AD-linked changes have also been reported in the
SCN including a reduction in the size, cell number and accumulation of NFTs, which may
collectively contribute to the wide range of visual complications reported in these patients [15,
17].
3. Visual abnormalities in Alzheimer’s disease and in patients with
dementia
A variety of visual abnormalities have been reported in patients with AD ranging from visuo-
constructional and visuo-perceptual dysfunctions, object agnosia, prosopagnosia to visual
hallucinations as well as simultanagnosia [5, 18, 19]. Patients with posterior cortical atrophy
(PCA), which is associated with degeneration of the posterior cortex, also report particular
difficulties with visual tasks often presenting with visual agnosia, visual neglect and visual
hallucinations [20, 21]. However, compared to memory loss, visual deficits have received little
attention and are thus poorly understood. Patients in the spectrum of, and leading to, clinical
AD show marked reductions in the number of RGC [22], narrowing of venous blood column
diameter and reduced venous blood flow rates [23], as well as optic nerve abnormalities such
as loss of axonal densities [24], RGCs [25] and increased receptor expression for advances
glycation end products [26]. Abnormalities are also observed in regions of AD brains that
synapse with the optic nerve and/or are associated with the visual processing pathway (Figure
2). Some examples include the loss of myelin, diminished nucleolar volume in the LGN, as
well as accumulation of lipofuscin (autofluorescent pigment granules) [27]. AD brains also
show the presence of NFT in the SC [28] (which receives ~10% of the RGC axons), as well as
the presence of Aβ/neuritic plaques in regions of the brain that are implicated in visual
attention and the control of eye movement. Aβ deposition has also been reported in the lens
of AD patients [29]. Additionally, histopathological evidence from post-mortem brains reveals
significant pathological changes in the visual processing regions of the brain including the loss
of pyramidal cells and reduced myelin in the outer laminae of the visual cortex [30–33]. A
comprehensive list of such neurological changes in areas of the brain associated with vision
has been described by Armstrong (2009) indicating the extensive nature of psyco-visual
abnormalities in patients with AD and dementia [29].
Not surprisingly, a large number of AD transgenic animal models also develop visual deficits
and have therefore been used to investigate retinal pathologies. These include, but are not
limited to, the Tg2576 [34], APPswe/PS1M146L and APPswe/PSΔE9 [35], 5xFAD [36, 37], and
P301S [38] mice. A wide range of retinal changes have been documented in these animals,
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including an age-dependent increase in APP/Aβ immunoreactivity in the neuroretina and
associated vasculature, the accumulation of Aβ plaques/ hyperphosphorylated tau in the nerve
fibre layer (NFL) and RGC, thinning of the RGC, as well as glial cell-derived neuro-inflam‐
matory responses within the retina [4]. Of importance, a number of these changes are common
to well-established animal models of retinal degeneration that are widely used to study AMD
[39, 40].
4. The degenerating retina: sight loss in old age
Despite the growing number of Alzheimer’s patients reporting visual complications, this has
received comparatively little attention. This may be due to several reasons including incom‐
plete diagnosis, associated complications, old age and cognitive impairment of patients as well
as lack of medical devices or tools to obtain a clear clinical diagnosis. Consequently, the breadth
and diversity of visual abnormalities in AD and dementia patients is yet to be fully recognised.
For example, analysis of published literature in NCBI PubMed using keywords such as ‘vision
and dementia’ (without the inclusion of any further search parameters) yielded only 447
citations in a 10-year period (between 2006 and June 2016), which is surprisingly few given the
frequency of visual abnormalities reported in these patients. In contrast, search terms such as
‘memory loss and cognitive decline’ yield 3062 citations over a similar period. Understanding
how the ageing retina becomes susceptible to degeneration and how it may affect the visual
pathway and/or perception by the brain could provide insights into the molecular and cellular
basis underlying visual abnormalities in AD. Here then is an opportunity to gain further
insights into how the world may be perceived by those suffering from AD and dementia.
Patients with retinopathies not only have damaged retinal tissues but also show impairments
in how visual information is relayed to and processed by the brain. For instance, visual
hallucinations classified under the term Charles Bonnet syndrome have been reported in
patients with late-onset visual disorders such as AMD [41]. Indeed, almost half of AMD
patients experience visual hallucinations, whilst a third report hallucinations that are distress‐
ing, intrusive and interfere with daily activities [41, 42]. AMD affects approximately 50 million
individuals globally [8, 43]. Unlike rare diseases caused by single-gene mutations, AMD is a
complex multifactorial disease which in many ways shows striking parallels with AD [4, 44,
45].
AMD exhibits an age-dependent prevalence with one in three individuals exhibiting some sign
of early disease by their seventh decade [43]. Currently, there are over half million AMD
patients in the United Kingdom (source: Macular Society), with comparable incidence rates in
Europe and other Western populations as reported by the European Eye Study (EUREYE) [46].
This puts a significant strain on national healthcare budgets with the direct annual cost of AMD
exceeding US$254 billion globally [14]. This figure is predicted to rise three-fold over the next
20 years as a result of increased life expectancy and reduced mortality rates [43]. This common,
irreversible blinding condition derives its name from the macula; the anatomical region
affected in disease. This specialised region, which we have introduced earlier, resides at the
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centre of the retina, temporal to the optic disk and is responsible for visual acuity and image
resolution (mediating focused central vision). Patients with AMD therefore suffer loss of
centrally mediated sight [45]. As the majority of patients are typically in the latter stages of
life, this has a disproportionate social impact, similar to some social issues encountered by
patients with AD and dementia [43].
The early stage of AMD is typically asymptomatic, and like AD, can remain so for many years
before clinical diagnosis. Hence, most patients with early AMD exhibit few or no obvious
visual symptoms [47], although a recent study found indications of early macular pathology
even in those aged between 35 and 44 [48]. A major pathological hallmark of early AMD is the
focal deposition of lipid-rich extracellular aggregates between the RPE and Bruch’s membrane
(Figure 1) [49]. With increasing age, such aggregates termed ‘drusen’ become common within
the periphery of normal healthy retinas as hard structures with well-defined borders [50]. In
contrast, patients with larger, soft drusen showing ill-defined borders (~125 μM) in the macula
region are considered to be at a higher risk of developing AMD [51]. Late AMD presents as
two distinct phenotypes; classified as geographic atrophy (dry) and neovascular (wet) AMD.
If early stages of the disease are excluded, the numbers of dry and wet AMD patients are
broadly similar [52]. Dry AMD is typified by gradual impairment of macular RPE cells and
death of overlying photoreceptors. By contrast, wet AMD is characterised by growth of new
leaky blood vessels from the underlying choroid (Figure 1). This results in accumulation of
fluid/sub-retinal swelling and scaring of the macula due to disruption of the outer BRB [45].
The growth of new vessels in wet AMD may be managed in most cases through monthly
intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors. In contrast, dry
AMD which affects the majority of AMD patients currently has no effective treatment [8].
Significant advances have been made in recent years to identify the genetic landscape of AMD
and related retinopathies [45]. However, this new knowledge has yet to provide insights into
key disease mechanisms, or translate into effective treatments against advancing blindness. It
is therefore vital to gain a better understanding of disease processes in the ageing retina before
effective AMD treatments can be developed. The recent discovery of the Alzheimer’s-
associated Aβ peptide, a well-known neurodegenerative agent associated in key stages of
AMD, has opened up the possibilities of studying sight loss from a novel perspective. Such
studies in a highly accessible tissue such as the retina could lead to a better understanding of
Aβ mechanisms as well as new insights into AD and dementia.
5. Age-related macular degeneration and Aβ
The healthy retina is constitutively exposed to Aβ. In fact, recent findings demonstrate that
Aβ synthesis occurs at local sites within the retinal environment including the RPE and RGCs
[53, 54]. The RPE is considered to be the principal source of Aβ in the posterior eye; a tissue
which also expresses APP [55]. The RPE also expresses the necessary factors for regulating
Aβ synthesis including β- and γ-secretase, as well as the Aβ-degrading enzyme neprilysin [56,
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57]. Furthermore, studies of mouse and bovine ocular fluids show the presence of Aβ in
picomolar to nanomolar quantities within both aqueous and vitreous humours [58].
The retina is a particularly useful tissue to study Aβ pathology as it is continuously exposed
to high photo-oxidative stresses throughout life, an ideal environment for Aβ accumulation
[44, 59, 60]. Hence, it is not surprising that the Aβ burden in the retina increases with advancing
age. To date, age-dependent accumulation of Aβ has been shown in multiple retinal locations
including photoreceptors, RPE, Bruch’s membrane and within the inner and outer retinal
vasculature [39, 55, 61, 62]. This pattern of Aβ accumulation has been reported both in rodent
models and in donor human eyes. For instance, Aβ deposits on photoreceptor were shown to
be abundant on mature POS or outer tips which are phagocytosed by RPE cells as part of the
daily visual cycle. Studies in wild-type mice show such Aβ-enriched outer tips of photorecep‐
tors to be enlarged, possibly due to impaired internalisation of POS by senescent RPE [39]. The
use of antibodies that recognise Aβ as well as APP also show immunoreactivity within the
cytoplasm of RPE cells that are adjacent to drusen [55]. Numerous studies also reveal the
presence of Aβ within drusen, which links a key clinical hallmark of AMD with Aβ [44, 55,
61–63]. Aβ within drusen have been shown organised into assemblies of approximately 2–10
μm in diameter. These spheres referred to as ‘amyloid vesicles’ were shown to have a concen‐
tric ring-like interior, permeated with Aβ immunoreactivity [55].
Interestingly, studies of post-mortem tissues show that the ageing human retina plays host to
a variety of Aβ assemblies. The use of various antibodies including 4G8, 6E10, WO1, WO2,
OC, A11 and 82E1 has revealed the presence of non-fibrillar oligomers, protofibrils and mature
amyloid fibrils [55, 61, 62]. Furthermore, different Aβ structures were evident in different
locations within amyloid vesicles. For example, in studies using 4G8, 6E10, WO1 and WO2
(which specifically recognise mature Aβ assemblies including protofibrils and mature fibrils),
immunoreactivity was typically observed within the outer shell of amyloid vesicles [55, 61,
63]. Conversely, studies investigating Aβ oligomers (antibodies A11 and M204) showed
preferential accumulation at the centre of drusen in close proximity to the inner collagenous
layer of Bruch’s membrane. Here, Aβ oligomers constituted the most abundant Aβ assembly
within drusen [39, 62]. Moreover, the presence of Aβ within drusen appeared to correlate with
drusen load as well as increasing age [63]. One study using a small number of patient samples
found that Aβ deposition were only present within drusen of AMD patients; supporting the
likelihood that Aβ accumulation is associated with more advanced forms of AMD [64].
As the RPE monolayer, which is strategically juxtaposed between the neuroretina and the outer
retinal vasculature (Figure 1), appears to be the main focus of Aβ deposition, it is not surprising
that Aβ has profound effects on its function. Of critical importance is the role of the RPE in
maintaining the immune-privileged state of the retina via the outer BRB. Oligomeric Aβ1–42 has
been shown to impair both early zonular occludens (ZO-1) and mid-to-late occludin tight
junctions in the RPE as well as induce actin cytoskeletal disorganisation. This suggests that
Aβ may compromise BRB integrity [65]. This is comparable to Aβ’s mode of action in the AD
brain which results in blood-brain barrier (BBB) disruption, increased BBB permeability and
endothelial cell dysfunction [66]. In fact recent studies have also shown a downregulation of
both ZO-1 and occludin upon application of Aβ to human cerebral microvascular endothelial
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cells. Such insights reveal striking parallels between neurodegenerative processes between the
ageing retina and brain, and how Aβ may play a key role in both pathologies [7, 66]. Similarly,
oligomeric Aβ exposure causes an upregulation of VEGF in both the brain and retina which
has been linked with AD and AMD. VEGF is essential in maintaining hippocampal plasticity
as well as cognitive function. However, VEGF upregulation is correlated with Aβ1–42 accumu‐
lation in AD brains resulting in neuronal cell death and BBB dysfunction [67]. In the eye, VEGF
is primarily secreted by the RPE; the increased levels of which are correlated with the neovas‐
cular form of AMD [8]. Anti-VEGF inhibitors consequently form the current the mainstay of
wet AMD treatments. Exposure of RPE cells to Aβ was shown to profoundly increase VEGF
secretion, which may contribute to such an undesirable pro-angiogenic retinal environment
[57].
Aβ also appears to play a central role in chronic inflammation of the ageing retina. Such
pathology is similar to inflammatory conditions found in AD brains [68]. For example,
transcriptome studies show enhanced complement gene expression in AD brains, particularly
those of complement C1q and C3 proteins [69, 70]. AMD involves a similar chronic inflam‐
matory response that is as yet incompletely understood. Here, compliment associated proteins
deposit within drusen alongside Aβ including compliment factor C3, compliment factor H and
the membrane attack complex, including its constituents C5, C6, C7 and C9 [55, 71]. Conse‐
quently, Aβ is thought to promote a pro-inflammatory retinal microenvironment where it co-
localises with complement factor H (CFH) and iC3b to induce compliment activation. Studies
have also shown the elevation of pro-inflammatory IL-1β, IL-6, IL-8, TNF-α and caspase-1
upon intravitreal Aβ injection in C57BL/6 J mice, as well as an increase in IL-8 and MMP-9
secretion levels by RPE upon exposure to Aβ1–42 [72, 73]. Microglial activation and engulfment
of Aβ have also been observed co-localised with retinal Aβ [39]. Similar pathology is also
reported in the brains of patients with AD [68].
Unsurprisingly, key features of AMD observed in human donor eyes can be recapitulated by
experimentally elevating retinal Aβ levels in wild-type mice. Our studies show that subretinal
injection of human recombinant Aβ1–42 at physiological doses (nM range) in C57BL/6 mice
induces RPE pigment abnormalities, RPE plasticity as well as photoreceptor outer segment
loss, hallmarks of AMD (Figure 3). Critically, using the 82E1 antibody specific to human Aβ,
we found experimentally introduced Aβ to co-localise to multiple retinal locations
corresponding to points of Aβ immunoreactivity reported in eyes of both AD [74, 75] and AMD
patients/mouse models [55, 61–63]. Hence, Aβ was shown to localise to RGC, the outer nuclear
layer, photoreceptors as well as the RPE-Bruch’s membrane interface [39]. Attempts by others
to elevate Aβ1–42 levels in the rodent vitreous resulted in apoptotic cells in photoreceptor and
nuclear layers as well as a significant reduction in RGC [76, 77]. However, our method of
elevating the retinal Aβ load via subretinal injection appears to mimic the senescent eye more
accurately (Figure 3), as the resulting phenotype certainly bears closer resemblance to human
AMD [55, 63, 64]. Additional evidence for ocular Aβ pathology comes from studies implicating
Aβ in other eye diseases such as supranuclear cataracts and glaucoma of which the latter is
common amongst AD patients [4].
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6. Similarities between AD and AMD
Degenerative processes in the ageing retina and brain share many common features. A major
pathological hallmark common to both AD and AMD is the formation of insoluble extracellular
aggregates that share several histochemical and compositional properties. Proteomic analyses
of the molecular components of senile plaques and drusen, for instance, has revealed common
proteins including tau, clusterin, vitronectin, apolipoprotein E (ApoE), serum amyloid P (SAP),
Aβ, metal ions, as well as pro-inflammatory factors and components of the compliment cascade
[4, 44, 78]. Histochemically, such deposits also stain with thioflavin T and Congo red which
confirms the presence of misfolded or amyloid proteins. However, there appears to be
differences between Aβ structures found in senile plaques and drusen. For instance, whilst
Figure 3. Subretinally injected Aβ in our mouse model recapitulates key aspects of retinal degeneration observed in
age-related macular degeneration (AMD). Wild-type C57BL/6 mice injected with nM concentrations of recombinant
human Aβ1–42 recapitulated key features of AMD. At 8 days post-injection, retinas contained RPE pigment abnormali‐
ties, RPE hypertrophy as well as photoreceptor outer segment loss, in contrast to healthy retinas of vehicle injected
mice. Confocal-immunofluorescence using the human Aβ-specific antibody 82E1 revealed focal Aβ deposits (green) in
the inner nuclear layer and in the RPE-Bruch’s membrane interface (arrows) corresponding to areas of Aβ synthesis/
accumulation reports in aged human retinas. RGC, retinal ganglion cells; IPL, inner plexiform layer; INL, inner nuclear
layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PIS, photoreceptor inner layer; POS, photoreceptor outer
segments; RPE, retinal pigment epithelium; BM, Bruch’s membrane; CH, choroid. DAPI (blue). Scale bar corresponds
to 100 μm.
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both types of extracellular protein deposits stain for Congo red, only senile plaques are positive
for the apple green birefringence dye specific for anti-parallel β-pleated sheets [49, 63].
Commonalities between AD and AMD are also observed in the manner in which highly
localised and significant damage occurs to lysosomes and mitochondria. In AD brains, these
include substantial increases in the size/number of endosomes, autophagosomes and lyso‐
somes; accumulation of lysosomal dense bodies in dystrophic neurites, as well as changes in
expression of lysosomal hydrolases such as cathepsins [2, 79]. Our studies as well as those of
others have shown selective permeabilisation of lysosomal membranes and release of lytic
content into the cytosol as a precursor to neuronal death, indicating a mechanism of early
cellular compromise correlated with a specific vulnerability in certain neurons [2, 79, 80].
Analysis of fixed tissues from AMD patients show extrudes of senescent RPE cytoplasm with
reactive lysosomes into the underlying Bruch’s membrane, and the accumulation of incom‐
pletely digested POS from overlying photoreceptors as lipofuscin within lysosomes [14].
Senescent postmitotic RPE cells with lipofuscin-filled lysosomes are a characteristic feature of
the ageing retina, and it accounts for as much as 20% of the cytoplasmic volume by the age of
80. Experiments using cell lines show the toxic nature of lipofuscin and its derivative N-
retinylidene–N-retinylethanolamine (A2E) that disrupts the phagocytic mechanisms of RPE
cells, impairs lysosomal proteases, inhibits the lysosomal ATPase proton pump and causes
leakage of lysosomal contents into the cytosol [81]. Dysfunctional lysosomes with
lipofuscin/A2E also generates reactive oxygen species (ROS), modify lipid peroxidation and
forms high molecular weight components that are stable within lysosomes. Moreover, A2E
causes detergent-like membrane disruption and inhibits lytic function. Healthy macula RPE
cells contain high levels of lysosomal enzymes acid phosphatase and cathepsin D, relative to
lysosomes from RPE cells in the nasal/mid-zone and peripheral retina [82]. Lysosomal enzyme
activity decreases by up to 50% when exposed to lipofuscin [83], indicating the regional
vulnerability of the macula in early AMD. Lysosomal damage may be further exacerbated by
the highly photoxidative RPE environment, providing ideal conditions for ROS generation
[84].
Mitochondria also show early damage in AD. Hence, post-mortem AD brains show signifi‐
cantly fewer mitochondria, abnormally enlarged as well as exceptionally small mitochondria,
damaged cristae, changes to organelle physiology, fission/fusion rates and transport defects
[85]. Mitochondrial abnormalities have also been linked to AMD primarily using studies of
cell lines showing a decrease in the number/area of RPE mitochondria, changes in redox
components and proteins involved in mitochondrial trafficking, increase in mitochondrial
DNA repair and decreased RPE mitochondrial respiration. A2E specifically damages mito‐
chondria inducing RPE apoptosis [60]. Our previous studies of a variant form of cystatin C
associated with AMD revealed a striking endoplasmic reticulum (ER)/Golgi to mitochondria
mis-localisation, which may have long-term consequences for RPE mitochondria [86, 87].
Recently, a strong association between the mitochondrial ARMS2 variant protein and AMD
was reported which appeared to drive AMD towards a neovascular phenotype [8].
Genetic risk factors between AMD and AD also indicate evidence of a shared aetiology. For
instance, studies have revealed a substantial link between allelic variants encoding compo‐
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nents of the alternative compliment cascade and the risk of developing AMD including factor
H, factor B and C3 [88–91]. Evidence for a similar genetic predisposition in AD has been
reported where polymorphisms within the CFH allele have been linked with an increased risk
of AD [92]. The large number of compliment cascade components that have been reported
within drusen and senile plaques, as well as the fact that chronic inflammation is a key driver
in both AD and AMD indicates that similar inflammatory responses may be involved in the
aetiologies of both AD and AMD. A strong genetic link has also been associated with ApoE, a
polymorphic gene encoding proteins ApoE2, ApoE3 and ApoE4 involved in lipid metabolism.
Amongst these, ApoE4 is somewhat confusingly associated with a lower risk of developing
AMD, whilst conferring an increased susceptibility to AD. Although the reason for this is not
clear, the positively charged nature of ApoE4 is speculated to interact somewhat differently
with Bruch’s membrane in the outer retina compared to its behaviour in the brain [93, 94]. The
opposite holds true with regard to ApoE2, which is protective in AD but is associated with a
higher risk of developing AMD. The reason for this also remains elusive [4]. Collectively, it
appears that ApoE dysregulation may affect Aβ metabolism/clearance in the retina and brain
in somewhat different ways, but which nonetheless triggers or drives pathology in these
respective tissues [93, 95, 96]. Several environmental factors are also shared between AD and
AMD that are thought confer increased susceptibility. These include cigarette smoking and
diet, as well as conditions such as high blood pressure, heart disease, stroke, diabetes, high
cholesterol levels and obesity [97–99]. In fact, a recent study conducted by the World Health
Organisation (WHO) revealed that smoking, which is the most prominent environmental risk
factor for AMD, almost doubled the risk of developing dementia [http://www.who.int/
tobacco/publications/en/]. The growing awareness of these shared pathologies in the senescent
brain and retina as well as the increasing sophistication of detection methods are beginning to
uncover closer links between AD and AMD. For instance, a recent study revealed the increased
risk of AMD amongst AD patients [100].
Collectively, this body of evidence strongly suggests a significant overlap between the
aetiologies of AMD and AD. This is not surprising, given the extensive visual complications
being reported in patients with AD and dementia. Initial detection typically relies on self-
diagnosis and/or observations by friends and family and is therefore often inconsistent, adding
to the potential delay in recognising these neuropathological conditions in a timely manner.
Hence, ocular studies have been proposed alongside studies to identify common biomarkers
so that those at greater risks may be identified relatively early before progressing to more
advanced stages.
7. Conclusions: amyloid beta and the retina as a biomarker for
Alzheimer’s disease
With increased sophistication of new imaging methods and related technologies, there is a
growing interest in developing reliable and cost-effective methods of identifying those at
greater risk of developing AD. These advances are welcome as current diagnostic techniques
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such as magnetic resonance imaging (MRI) do not always provide sufficient image resolution
to detect incipient brain pathology, whilst positron emission tomography (PET) is prohibi‐
tively expensive and is not widely available [4]. Consequently, the most conclusive diagnosis
of AD is only made following a brain autopsy, which is of little use as a predictor of disease.
Various studies have explored the possibility of measuring peripheral Aβ in the blood or
cerebrospinal fluid (CSF) as prognostic markers of disease. CSF as a biomarker has consistently
been shown to provide an accurate indication of underlying AD pathology but is an invasive
and costly procedure [4]. In contrast, plasma Aβ presents a more cost-effective and a less
invasive method of diagnosis, but has proved less successful in identifying those at higher risk
[101]. Interestingly, a recent study revealed that plasma Aβ levels accurately correlated across
progressive stages of AMD [102]. Nonetheless, inconclusive data from other studies, as well
as evidence from AD patients, suggest that such approaches require a more rigorous level of
standardisation and further fine-tuning before clinical application [101].
In summary, we propose that the eye is not only a useful organ to study Aβ pathology but that
a better understanding of retinal dystrophies may reveal insights into AD and dementia. The
eye is amiable to manipulation and study in a way that the brain is not, thus providing a
powerful diagnostic tool or an anatomical window to detect potential brain pathology.
Consequently, non-invasive retinal imaging techniques may be exploited to measure the
retinal Aβ burden and thus identify potential individuals at risk of developing AD. Such
methods have already been demonstrated by those using retinal photography, scanning laser
ophthalmoscopy (SLO), Doppler blood flowmetry and optical coherence tomography (OCT)
to assess retinas of AD and dementia patients [23, 103, 104]. For example, funduscopy is widely
used to assess the retina, which often detects the first clinical signs of AMD such as macular
drusen. Using such an apparatus, a pilot study found a significant correlation between the
appearance of peripheral retinal drusen and AD [103]. Furthermore, Doppler blood flowmetry
has been used to measure retinal blood vessel diameters in AD patients. These studies show
that decreased vessel diameter correlated with disease progression alongside impaired retinal
blood-flow and circulation abnormalities [23]. Advances in OCT were also used to demonstrate
NFL abnormalities in patients with open-angle glaucoma [104]. However, this may be of
limited value as an early-disease indicator since NFL thinning only becomes apparent in
advanced AD [23]. SLO, another non-invasive approach, is used to reliably assess optic nerve-
head damage and optic disc topography in glaucoma patients [105], pathologies that are also
evident in some AD patients [24]. Finally, trials have been undertaken in AD rodent models
using systemic injections of the naturally occurring food ingredient curcumin, which fluores‐
ces when bound to retinal Aβ [74]. Use of this compound has the added advantage of being
able to traverse the BRB and BBB, demonstrating successfully use of a non-invasive retinal
imaging in AD-Tg mice which correlated the extent of retinal Aβ with plaque load and disease.
Curcumin labelling of retinal Aβ deposits in these mice was detected as early as 2.5 months,
whereas Aβ deposition in the brain was only apparent after 5 months [74] supporting the idea
that the aged eye may function as an early warning system for incipient brain pathology. As
curcumin has also been shown to reliably label Aβ deposits/structures in post-mortem human
retinas [74], its use could easily be extended to non-invasively detecting retinal Aβ in AD
clinics. Hence, there is considerable interest in the pharmaceuticals industry to identify both
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natural compounds as well as synthetic agents capable of reliably binding Aβ [106, 107]. Such
studies will be highly informative in providing further insights into the role of Aβ in the ageing
retina and brain, and help extend current understanding of shared pathologies in these
intimately linked tissues.
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